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CASE REPORT
A 71-year-old man, never-smoker, with anaplastic lym-
phoma kinase (ALK)-positive stage IV metastatic lung adeno-
carcinoma presented to our clinic to discuss treatment options. 
In February 2013, he developed sudden-onset lumbar back 
pain. A lumbar spine magnetic resonance imaging study was 
obtained on February 27, 2013, which showed mild-to-mod-
erate acute compression deformity at L3 vertebral body. His 
symptoms persisted, and on May 1, 2013, a kyphoplasty was 
performed. At the time of surgery, a bony lesion was found 
and was biopsied consistent with metastatic lung adenocarci-
noma. An ALK (2p23) rearrangement was detected by the US 
Food and Drug Administration–approved fluorescence in situ 
hybridization assay. At the time of diagnosis, a positron emis-
sion tomography/computed tomography showed a primary 
mass in the left hilum measuring 6.4 cm × 4.6 cm × 7.5 cm 
with metastatic disease seen in the right supraclavicular lymph 
nodes, mediastinum, left hilar region, T8, L5, and L3 verte-
bral bodies, and left iliac bone (Fig. 1A–C). A brain magnetic 
resonance imaging showed no evidence of metastatic disease.
On June 4, 2013, he was started on crizotinib (Xalkori; 
Pfizer, New York, NY) 250 mg PO twice daily and zoledronic 
acid monthly. He initially tolerated crizotinib well, and his bone 
pain improved. On August 20, 2013, he developed an erythema-
tous rash that began with swelling and redness in sun-exposed 
areas on his lower extremities bilaterally and spread to sun-
exposed areas of his upper extremities, his neck, and his face. 
His torso and back were spared (Fig. 2A). As the rash evolved, 
there were marked areas of exfoliation (Fig. 2B). He was started 
on methylprednisolone, and his rash improved. He continued on 
crizotinib. However, when the methylprednisolone was tapered, 
his rash flared again in the same areas with even more exfo-
liation and weeping of his skin. He was started again on meth-
ylprednisolone, and crizotinib was discontinued on September 
10, 2013. His rash slowly improved. On September 23, 2013, 
he was rechallenged with 50% dose-reduced crizotinib (250 mg 
PO daily) and again developed a similar photosensitive rash 
within 3 days in the same sun-exposed areas and crizotinib was 
again discontinued. Throughout this time, he was maintained 
on all his other medications, including oxycontin, oxycodone, 
lisinopril, and omeprazole, and thus these medications unlikely 
contributed to the development of his photosensitive rash. His 
photosensitive rash began resolving 2 to 3 weeks later but did 
not completely resolve until 6 weeks after permanently dis-
continuing crizotinib. A repeat positron emission tomography/
computed tomography was performed on September 23, 2013, 
showing a dramatic improvement in his lymphadenopathy and 
distant metastatic disease with a significant reduction in the size 
of his primary left hilar mass (Fig. 1D–F).
DISCUSSION
Here, we report a patient with ALK-positive metastatic 
lung adenocarcinoma who developed a severe photosensitive 
rash to crizotinib. He had a significant response to crizotinib 
therapy but was unable to continue because of skin toxicity. 
Crizotinib is US Food and Drug Administration approved for 
the treatment of ALK-positive advanced lung adenocarcinoma, 
and common reported toxicities in clinical trials include visual 
disturbances, diarrhea, transaminitis, fatigue, and edema. In 
both phase I1 and phase III2 trials, there were rashes reported 
in patients receiving crizotinib at a frequency of 11% and 9%, 
respectively, with no reported grade III or IV rashes. The rash 
that our patient developed was likely because of crizotinib as 
he developed the same rash soon after re-exposure to crizo-
tinib. It qualifies as a grade IV rash, given the marked areas 
of exfoliation. To our knowledge, this is the first report of a 
severe photosensitive exfoliative rash caused by crizotinib.
Skin toxicity is a common and well-known side effect 
of other small molecule tyrosine kinase inhibitors particu-
larly epidermal growth factor receptor (EGFR) inhibitors 
such as erlotinib as EGFR is highly expressed in epidermal 
cells.3 Photosensitive dermatitis is not a common association 
with small molecule tyrosine kinase inhibitors but has been 
described in patients taking imatinib for chronic myelogenous 
leukemia (CML)4 and vandetanib, an EGFR, vascular endothe-
lial growth factor, and rearranged during transfection (RET) 
kinase inhibitor.5 It is unusual for patients taking crizotinib to 
develop severe skin toxicity. Further studies and clinical expe-
rience will be needed to determine whether this photosensitiv-
ity dermatitis caused by crizotinib is related to ALK inhibition 
itself, an off-target effect, or mediated by host immunity.
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FIGURE 1.  Positron emission tomog-
raphy/computed tomography shows 
significant response to crizotinib. Maximum 
intensity projection image (A), axial fusion 
image through the hilum (B), and axial 
fusion image through the left lower lobe of 
the lung (C) before treatment with crizo-
tinib and corresponding images (D, E, and 
F) after treatment with crizotinib.
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FIGURE 2.  Images of exfoliative photosensi-
tive rash after treatment with crizotinib. A, 
Representative images demonstrating rash in 
 sun-exposed areas, and (B) close up of his left 
upper extremity showing exfoliation.
